Литература. 
Статинотерапия у больных инсультом: SPARCL ставит новые задачи

1. Scandinavian Simvаstatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvаstatin Survival Study (4S). Lancet 1994; 344: 1383−1389.

2. Sacks F.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001−1009.

3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7−22.

4. Sever P. S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004; 64 Suppl 2: 43−60.

5. Colhoun H.M., Betteridge D.J., Durrington P.N. et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435): 685−96.

6. Nissen S.E., Tuzcu E.M., Schoenhagen P. et al.; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352 (1): 29−38.

7. Waters D.D., Guyton J.R., Herrington D.M. et al.; Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93: 154−8.

8. Amarenco P., Bogousslavsky J., Callahan A. III et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549−559.

9. Goldstein L.B., Amarenco P., Szarek M. et al.; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70 (24 Pt 2): 2364−70.

10. Karam J.G., Loney-Hutchinson L., McFarlane S.I. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. J Cardiometab Syndr 2008; 3 (1): 68−69.

11. Rodriguez-Yanez M., Agulla J., Rodriguez-Gonzalez R. et al. Statins and Stroke. Ther Adv Cardiovasc Dis 2008; 2 (3): 157−166.

12. Gedikli O., Baykan M. Statins in stroke prevention. Anadolu Kardiyol Derg 2008; 8 (3): 217−22.

13. Bersano A., Ballabio E., Lanfranconi S. et al. Statins and stroke. Curr Med Chem 2008; 15 (23): 2380−92.

14. Scheen A.J., Radermecker R.P., Sadzot B. Statin for the brain: update in 2008. Rev Med Liege 2008; 63 (5−6): 287−92.

15. Athyros V.G., Kakafika A.I., Tziomalos K. et al. Statins for the prevention of first or recurrent stroke. Curr Vasc Pharmacol 2008; 6 (2): 124−33.

16. Fitchett D.H., Goodman S.G., Langer A. Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Can J Cardiol 2008; 24 (9): 705−8.

17. Adams R.J., Albers G., Alberts M.J. et al. Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 2008; 39: 1647−1652.